COMPASS Pathways plc（股票代码：CMPS）今日盘中大涨5.03%，引起了市场的广泛关注。
消息面上，美国食品药品监督管理局（FDA）表示将采取措施，以加快针对严重精神疾病的新疗法的研发进程，此举是响应唐纳德·特朗普总统签署的一项行政命令，旨在加快基于迷幻药的医学研究和治疗的普及。FDA表示将向三家开发迷幻药物疗法的公司发放特别优先券，这被视为对Compass Pathways等迷幻药物开发商的重大利好。
此外，COMPASS Pathways公司宣布，FDA已正式批准其新药申请（NDA）的滚动审评请求，同时授予专员国家优先审评券。这一重要进展将显著加速该公司创新疗法的审评进程，为其核心产品的商业化奠定重要基础。受这些监管利好消息推动，公司股价在交易时段内显著走强。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.